Cspc Megalith Biopharmaceutical Co.,ltd.

This study tests whether a new drug combination (SYS6010 plus Enlonstobart) can shrink tumors or slow cancer growth in people with head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for advanced disease will rec…

This study is testing a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not improved with standard treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to find the safest dose and…

This study tests a new drug called SYS6010 against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to targeted therapy (EGFR TKI). About 380 adults aged 18-75 will be randomly assi…